Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-07976016 + PF-08642534
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PF-07976016 + PF-08642534 is an investigational oral combination therapy that was being developed by Pfizer for the treatment of obesity. The combination consists of PF-07976016, an orally bioavailable small molecule antagonist of the gastric inhibitory polypeptide receptor (GIPR), and PF-08642534 (also known as YP05002), an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist licensed from YaoPharma. By combining GIPR antagonism with GLP-1R agonism, the therapy aimed to achieve enhanced weight loss compared to GLP-1R agonism alone. However, in August 2026, Pfizer announced the discontinuation of PF-07976016 following a review of Phase 2a clinical data, which effectively halted the development of this specific combination.
- Other names
- PF-07976016 + YP-05002PF-07976016 + YP05002
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on PF-07976016 + PF-08642534.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-07976016 + PF-08642534.